JP6294221B2 - 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント - Google Patents

腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント Download PDF

Info

Publication number
JP6294221B2
JP6294221B2 JP2014501372A JP2014501372A JP6294221B2 JP 6294221 B2 JP6294221 B2 JP 6294221B2 JP 2014501372 A JP2014501372 A JP 2014501372A JP 2014501372 A JP2014501372 A JP 2014501372A JP 6294221 B2 JP6294221 B2 JP 6294221B2
Authority
JP
Japan
Prior art keywords
seq
antibody
cancer
antigen
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014501372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515600A5 (https=
JP2014515600A (ja
Inventor
ジル・ベルナール・トレンブレイ
アンナ・エヌ・モレティス
トライアン・スリー
マリオ・フィリヨン
Original Assignee
アー・デー・ツェー・セラピューティクス・エス・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アー・デー・ツェー・セラピューティクス・エス・アー filed Critical アー・デー・ツェー・セラピューティクス・エス・アー
Publication of JP2014515600A publication Critical patent/JP2014515600A/ja
Publication of JP2014515600A5 publication Critical patent/JP2014515600A5/ja
Application granted granted Critical
Publication of JP6294221B2 publication Critical patent/JP6294221B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
JP2014501372A 2011-03-31 2012-03-28 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント Expired - Fee Related JP6294221B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161470063P 2011-03-31 2011-03-31
US61/470,063 2011-03-31
US201161533346P 2011-09-12 2011-09-12
US61/533,346 2011-09-12
PCT/CA2012/000296 WO2012129668A1 (en) 2011-03-31 2012-03-28 Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017235147A Division JP6650432B2 (ja) 2011-03-31 2017-12-07 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント

Publications (3)

Publication Number Publication Date
JP2014515600A JP2014515600A (ja) 2014-07-03
JP2014515600A5 JP2014515600A5 (https=) 2015-06-18
JP6294221B2 true JP6294221B2 (ja) 2018-03-14

Family

ID=46929256

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014501372A Expired - Fee Related JP6294221B2 (ja) 2011-03-31 2012-03-28 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント
JP2017235147A Expired - Fee Related JP6650432B2 (ja) 2011-03-31 2017-12-07 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント
JP2020005907A Ceased JP2020074785A (ja) 2011-03-31 2020-01-17 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017235147A Expired - Fee Related JP6650432B2 (ja) 2011-03-31 2017-12-07 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント
JP2020005907A Ceased JP2020074785A (ja) 2011-03-31 2020-01-17 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント

Country Status (24)

Country Link
US (5) US8937163B2 (https=)
EP (3) EP3511345A1 (https=)
JP (3) JP6294221B2 (https=)
KR (2) KR102140984B1 (https=)
CN (2) CN106146664B (https=)
AU (1) AU2012234754B2 (https=)
BR (1) BR112013025198A2 (https=)
CA (3) CA2893376A1 (https=)
CY (1) CY1122156T1 (https=)
DK (2) DK3173427T3 (https=)
EA (1) EA038979B1 (https=)
ES (2) ES2615387T3 (https=)
HR (1) HRP20191590T1 (https=)
HU (1) HUE045943T2 (https=)
IL (3) IL228434B (https=)
LT (1) LT3173427T (https=)
MX (1) MX352373B (https=)
PL (1) PL3173427T3 (https=)
PT (1) PT3173427T (https=)
RS (1) RS59080B1 (https=)
SI (1) SI3173427T1 (https=)
SM (1) SMT201900505T1 (https=)
WO (1) WO2012129668A1 (https=)
ZA (1) ZA201307027B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020074785A (ja) * 2011-03-31 2020-05-21 アー・デー・ツェー・セラピューティクス・エス・アー 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
HUE056289T2 (hu) 2017-02-08 2022-02-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
IL266153A (en) * 2019-04-18 2019-07-31 Aharon Anat Extracellular vesicles derived from t cells containing a chimeric antigen receptor
GB201908128D0 (en) * 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN116783301A (zh) * 2021-01-07 2023-09-19 加拿大国家研究委员会 使用稳定细胞系生产生物制品的严格调节的可诱导表达系统
CN120239615A (zh) 2022-08-12 2025-07-01 艾比生物制品公司 使用双特异性结合剂降解egfr
WO2024108193A2 (en) 2022-11-18 2024-05-23 Epibiologics, Inc. Degradation of cmet using a bispecific binding agent

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US662392A (en) 1899-12-12 1900-11-27 Friedrich Wilhelm Buehne Method of making metal wool.
US5075447A (en) 1984-09-17 1991-12-24 Hoffmann-La Roche Inc. Ruthenium complexes useful as carriers for immunologically active materials
DK365785A (da) 1984-09-17 1986-03-18 Hoffmann La Roche Metalcomplexer
GB8601646D0 (en) 1986-01-23 1986-02-26 Davidson R S Binding assay & reagent
US5585279A (en) 1986-01-23 1996-12-17 Davidson; Robert S. Time-resolved luminescence binding assays using a fluorescent transition metal label other than ruthenium
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
DE69028552T2 (de) 1989-12-28 1997-03-06 The Upjohn Co., Kalamazoo, Mich. Diaromatische substituierte verbindungen gegen den aids-virus
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
AU4017695A (en) 1994-10-28 1996-05-23 Procept, Inc. Ruthenium complexes and their use as immunosuppressive agents
US5708022A (en) 1994-10-28 1998-01-13 Procept, Inc. Method for inhibiting immune response
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
NZ502303A (en) 1997-06-18 2002-02-01 Ulrich J Krull Nucleic acid biosensor system & diagnostic use
WO1999031513A1 (en) 1997-12-15 1999-06-24 Lakowicz Joseph R Method and composition for characterizing a sample containing a sample lipid and an assay kit
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
EP1077989A4 (en) 1998-05-13 2002-01-02 Ludwig Inst Cancer Res ANTIGEN WITH TUMOR ASSOCIATION ENCODED BY THE ANTISENSE STRAND OF A NEW GENE WITH UBIQUISTIC EXPRESSION
ES2299244T3 (es) 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US20020106678A1 (en) 1998-06-30 2002-08-08 Robishaw Janet D. cDNA clones encoding human G protein gamma subunits
JP2002519428A (ja) 1998-07-02 2002-07-02 メルク エンド カムパニー インコーポレーテッド プレニル−タンパク質トランスフェラーゼの阻害剤
US6288221B1 (en) 1998-08-20 2001-09-11 Duke University Methods of synthesis of halogen base-modified oligonucleotides and subsequent labeling with a metal-catalyzed reaction
AU6136599A (en) 1998-09-08 2000-03-27 University Of Maryland At Baltimore Low frequency modulation sensors using nanosecond fluorophores
US6806089B1 (en) 1998-09-08 2004-10-19 University Of Maryland, Baltimore Low frequency modulation sensors using nanosecond fluorophores
AU1223400A (en) 1998-10-22 2000-05-08 Phillip B. B. Moheno Novel pterin antineoplastic agents
EP1158984A4 (en) 1998-10-29 2003-05-21 Merck & Co Inc Inhibitors of prenyl protein transferase
AU3268500A (en) 1999-03-19 2000-10-09 Anormed Inc. Pharmaceutical compositions comprising metal complexes
US6872519B1 (en) 1999-04-27 2005-03-29 Mirus Bio Corporation In vitro process for selecting phage resistant to blood inactivation
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CZ2002959A3 (cs) 1999-09-17 2002-07-17 Millennium Pharmaceuticals, Inc. Inhibitory faktoru Xa
WO2001046209A1 (en) 1999-12-20 2001-06-28 Fluorrx, Inc. Fluorescent probes
US20030219806A1 (en) 2000-02-22 2003-11-27 Millennium Pharmaceuticals, Inc. Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
US7585839B2 (en) 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
US20030215860A1 (en) 2000-02-29 2003-11-20 Millennium Pharmaceuticals, Inc. Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor
WO2001070979A2 (en) 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
WO2001098468A2 (en) 2000-06-16 2001-12-27 Incyte Genomics, Inc. Proteases
WO2002006339A2 (en) 2000-07-03 2002-01-24 Curagen Corporation Proteins and nucleic acids encoding same
US20050053930A1 (en) 2000-07-18 2005-03-10 David Anderson Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US7030236B2 (en) 2001-03-09 2006-04-18 Mona Savitri Jhaveri Antisense oligonucleotides tarageting folate receptor alpha, and the use thereof
AU2002258518A1 (en) 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20030065157A1 (en) 2001-04-04 2003-04-03 Lasek Amy W. Genes expressed in lung cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
AU2002309583A1 (en) 2001-04-18 2002-11-05 Protein Desing Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002257440A1 (en) 2001-05-07 2002-11-18 National Research Council Of Canada Enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2002102235A2 (en) 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040053824A1 (en) 2001-06-29 2004-03-18 Tang Y Tom Extracellular matrix and cell adhesion molecules
US20030099974A1 (en) 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
KR20100043294A (ko) 2001-08-31 2010-04-28 비티지 인터내셔널 리미티드 항암제로서 사용되는 시클로펜타[ｇ]퀴나졸린 화합물
US7528141B2 (en) 2001-08-31 2009-05-05 Btg International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
BR0214295A (pt) 2001-11-19 2004-11-09 Elan Pharm Inc Composto, método para tratar um paciente que tem ou prevenir um paciente de adquirir uma doença ou condição, e, método para produzir um composto
WO2003047526A2 (en) 2001-11-30 2003-06-12 Incyte Genomics, Inc. Cell adhesion and extracellular matrix proteins
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
WO2003057725A2 (en) 2002-01-09 2003-07-17 University Of Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2003062290A1 (en) 2002-01-16 2003-07-31 Biocompatibles Uk Limited Polymer conjugates
EP1478328B1 (en) 2002-01-28 2013-06-05 Keraplast Technologies Ltd. Bioactive keratin peptides
US6962910B2 (en) 2002-02-01 2005-11-08 Virginia Tech Intellectual Properties, Inc. Supramolecular complexes as photoactivated DNA cleavage agents
WO2003068054A2 (en) 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification of ovarian cancer tumor markers and therapeutic targets
DE10206616A1 (de) 2002-02-15 2003-09-04 Qiagen Gmbh Verfahren zur Reduktion der Background-Kontamination nach Markierungsreaktionen
AU2003228267A1 (en) 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US20040101874A1 (en) 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
PL375064A1 (en) 2002-05-20 2005-11-14 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1422242A1 (en) 2002-11-22 2004-05-26 Emory University Plastic and elastic protein copolymers
JP2006519008A (ja) 2003-02-10 2006-08-24 独立行政法人産業技術総合研究所 哺乳動物細胞の調節
WO2004087874A2 (en) 2003-03-28 2004-10-14 Nuvelo, Inc. Novel nucleic acids and polypeptides
AU2004240765B2 (en) 2003-05-20 2009-03-19 Cellpep Sa Modified antiviral peptides with increased activity and cell membrane affinity
CA2526393A1 (en) 2003-05-21 2004-12-02 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
US20050008649A1 (en) 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
US20060078941A1 (en) 2003-06-09 2006-04-13 Santin Alessandro D Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
WO2005004795A2 (en) 2003-06-09 2005-01-20 University Of Cincinnati Compositions and methods for targeted drug delivery
WO2006003352A1 (en) 2004-07-06 2006-01-12 Warwick Effect Polymers Limited Living radical polymerization initiator comprising a functional group capable of reacting with polyeptides or the like, comb polymer obtained therewith, polypeptide conjugates and drugs obtained therefrom
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
GB0318096D0 (en) 2003-08-01 2003-09-03 Queen Mary & Westfield College Vaccine
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
US20070178458A1 (en) 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7202234B2 (en) 2003-10-24 2007-04-10 Eisai Co., Ltd. Compounds and methods for treating Toll-like receptor 2-related diseases and conditions
US20050153333A1 (en) 2003-12-02 2005-07-14 Sooknanan Roy R. Selective terminal tagging of nucleic acids
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
WO2005070456A2 (en) 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
WO2005066337A2 (en) 2004-01-09 2005-07-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
CA2555145A1 (en) 2004-02-06 2005-08-25 Wyeth Diagnosis and therapeutics for cancer
JP4912894B2 (ja) 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
EA200601575A1 (ru) 2004-03-01 2007-06-29 Пептера Фармасьютикалс Лтд. Казеиновые пептиды и их терапевтическое применение
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7553944B2 (en) 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
US20080280317A1 (en) 2004-08-27 2008-11-13 Northeastern University Comprehensive Characterization Of Complex Proteins At Trace Levels
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
WO2006027202A1 (en) 2004-09-06 2006-03-16 Unite De Recherche En Biotherapie Et Oncologie (Rubio) Generation of multiparent cell hybrids
JP2008512490A (ja) 2004-09-08 2008-04-24 チェルシー・セラピューティクス，インコーポレイテッド 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
US8247371B2 (en) 2004-10-14 2012-08-21 Yale University Therapy with Clostridium perfringens enterotoxin to treat ovarian and uterine cancer
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
JP2008526749A (ja) 2005-01-04 2008-07-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 自己アセンブリするペプチドナノファイバーを用いたｐｄｇｆの徐放性の送達
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
EP1847533B1 (en) 2005-01-27 2013-08-14 Asahi Kasei Pharma Corporation Six-membered heterocyclic compound and the use thereof
US8007811B2 (en) 2005-02-14 2011-08-30 Epitopix, Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
CN101160524A (zh) 2005-02-24 2008-04-09 西米尼斯公司 用于生物样品分类的组合物和方法
EP1861498A4 (en) 2005-03-17 2009-06-24 Ca Nat Research Council EXPRESSION VECTORS FOR TRANSIENT GENETIC EXPRESSION AND MAMMALIAN CELLS EXPRESSING THE SAME
EP1863800A4 (en) 2005-03-17 2011-05-04 Harvard College SYNTHESIS OF AVRAINVILLAMID, STEPHACIDINE B AND ANALOGUE THEREOF
FR2885525B1 (fr) 2005-05-13 2009-09-18 Urodelia Sa Medicament notamment anti-cancereux, destine a des traitements par immunotherapie, en particulier autologue
KR101604799B1 (ko) 2005-06-13 2016-03-28 클리브랜드 바이오랩스, 아이엔씨. 리포펩티드를 사용하여 아폽토시스에 대항하는 보호방법
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
BRPI0612287A8 (pt) 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
WO2007005249A2 (en) 2005-06-29 2007-01-11 Hyperbranch Medical Technology, Inc. Nanoparticles and dendritic-polymer-based hydrogels comprising them
US7494788B2 (en) 2005-07-11 2009-02-24 Molecular Kinetics, Inc. Entropic bristle domain sequences and their use in recombinant protein production
US7820790B2 (en) 2005-07-13 2010-10-26 Amgen Mountain View Inc. IL-6 binding proteins
US20090005268A1 (en) 2005-07-18 2009-01-01 Epigenomics Ag Compositions and Methods for Cancer Diagnostics Comprising Pan-Cancer Markers
GB0516058D0 (en) 2005-08-04 2005-09-14 Oxford Genome Sciences Uk Ltd New protein isoforms and uses thereof
GB0517293D0 (en) 2005-08-24 2005-10-05 Cancer Rec Tech Ltd Vectors and uses thereof
PL1931998T3 (pl) 2005-09-15 2010-11-30 Alk Abello As Sposób ilościowego oznaczania alergenów
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
DK1954274T3 (da) 2005-11-10 2011-01-31 Chemocentryx Inc Substituerede quinoloner og fremgangsmåder til anvendelse
EP1954134B1 (en) 2005-11-23 2011-09-14 Merck Sharp & Dohme Corp. Process for synthesizing a 2-phenyl-1h-phenantrho[9,10-d]imidazole derivative
KR101049859B1 (ko) 2007-11-28 2011-07-19 대한민국 Ｎ-말단 ｐＩ 값 조절에 의한 수용성 재조합 단백질 생산방법
WO2007101441A1 (en) 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
JP5167155B2 (ja) 2006-03-09 2013-03-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法
CA2642819C (en) 2006-03-10 2015-06-09 Warwick Effect Polymers Ltd. Sugar polymers
WO2007110755A1 (en) 2006-03-27 2007-10-04 Medical Therapies Limited Prophylaxis or treatment of cardiovascular inflammation
JP5093783B2 (ja) 2006-04-20 2012-12-12 クリングルファーマ株式会社 Ｈｇｆ前駆体蛋白質改変体及びその活性型蛋白質
WO2007131191A2 (en) 2006-05-05 2007-11-15 Perkinelmer Life And Analytical Sciences Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases
CA2652247C (en) 2006-05-08 2015-11-17 Adaerata, Limited Partnership Chimeric pcsk9 proteins, cells comprising same, and assays using same
US20120128661A1 (en) 2006-06-23 2012-05-24 Alethia Biotherapeutics Inc. Polynucleotide and polypeptide sequences involved in cancer
ES2444695T3 (es) 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
EP2041556A1 (en) 2006-06-28 2009-04-01 RGB Technologies AB A sensor kit and a system for detecting an analyte in a test environment
US8198046B2 (en) 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
WO2008012362A2 (en) 2006-07-27 2008-01-31 Oxford Genome Sciences (Uk) Ltd New protein isoforms and uses thereof
EP2052088A2 (en) 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008029031A2 (fr) 2006-09-07 2008-03-13 Laurence Faure Test pharmaco diagnostique ciblant l' oncologie
WO2008033932A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors
CN101663308A (zh) 2006-10-30 2010-03-03 桑尔克斯药品公司 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
CA2672860C (en) 2006-12-28 2013-01-29 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
WO2008086426A2 (en) 2007-01-09 2008-07-17 Cleveland Biolabs, Inc. Methods for increasing and mobilizing hematopoietic stem cells
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
WO2008124483A1 (en) 2007-04-04 2008-10-16 Specigen, Inc. Protein cage immunotherapeutics
WO2009009186A2 (en) 2007-04-13 2009-01-15 The Regents Of The University Of California Receptors useful for gas phase chemical sensing
JP2010526091A (ja) 2007-04-30 2010-07-29 インテザイン テクノロジーズ， インコーポレイテッド 癌の処置のための生物学的な標的基の改変
US20080306007A1 (en) 2007-04-30 2008-12-11 Newcastle Innovation Limited Agents for prophylaxis or treatment of neurological related diseases and conditions
US8143372B2 (en) 2007-05-21 2012-03-27 Children's Hospital & Research Center Oakland Synthetic regulators of ferritin protein nanocage pores and methods of use thereof
US20090176664A1 (en) 2007-06-01 2009-07-09 Keting Chu High density peptide arrays containing kinase or phosphatase substrates
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
US9018138B2 (en) 2007-08-16 2015-04-28 The Johns Hopkins University Compositions and methods for generating and screening adenoviral libraries
CA2695309A1 (en) 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
ES2897492T3 (es) 2007-11-05 2022-03-01 Nordic Bioscience Imaging As Marcadores bioquímicos para la evaluación de riesgos de CVD
US20100298368A1 (en) 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
EP2071334A1 (en) 2007-12-14 2009-06-17 Transmedi SA Compositions and methods of detecting TIABS
WO2009111088A2 (en) 2008-01-02 2009-09-11 The Johns Hopkins University Antitumor immunization by liposomal delivery of vaccine to the spleen
US20090239229A1 (en) 2008-03-14 2009-09-24 Dnar, Inc DNA Repair Proteins Associated With Triple Negative Breast Cancers and Methods of Use Thereof
US8568709B2 (en) 2008-03-20 2013-10-29 University Health Network Thymidylate kinase fusions and uses thereof
WO2009134370A2 (en) 2008-04-30 2009-11-05 University Of Vermont And State Agricultural College Methods and products relating to gsk3 beta regulation
ES2500616T3 (es) 2008-05-09 2014-09-30 Evonik Corporation Polímeros elastoméricos biocompatibles y biodegradables
EP2772251B1 (en) 2008-05-26 2021-03-03 Universität Zürich Protamine/RNA nanoparticles for immunostimulation
US8071807B2 (en) 2008-07-03 2011-12-06 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
EP2309853A4 (en) 2008-08-01 2012-04-25 Lixte Biotechnology Inc METHOD FOR CELL MITITULATING BY INHIBITION OF SERIN / THREONINE PHOSPHATASE
US9126953B2 (en) 2008-08-08 2015-09-08 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
EP2451844B1 (en) * 2009-07-10 2015-04-22 Innate Pharma Tlr3 binding agents
EP2486149B1 (en) 2009-08-06 2015-06-17 John Wayne Cancer Institute Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
WO2011054112A1 (en) 2009-11-03 2011-05-12 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of kidney associated antigen 1
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
US20110233107A1 (en) 2010-03-23 2011-09-29 Emily Jainine Lockett Personal Cosmetic Palette
SI3173427T1 (sl) * 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020074785A (ja) * 2011-03-31 2020-05-21 アー・デー・ツェー・セラピューティクス・エス・アー 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント

Also Published As

Publication number Publication date
CN106146664B (zh) 2021-09-07
CY1122156T1 (el) 2020-11-25
JP2020074785A (ja) 2020-05-21
IL266452B (en) 2020-10-29
EP2691421B1 (en) 2016-11-09
EP3173427A1 (en) 2017-05-31
CN103492418B (zh) 2016-06-29
KR102140984B1 (ko) 2020-08-06
ES2743913T3 (es) 2020-02-21
DK2691421T3 (en) 2017-02-20
PT3173427T (pt) 2019-09-17
CA2829105A1 (en) 2012-10-04
IL266452A (en) 2019-06-30
JP6650432B2 (ja) 2020-02-19
EP2691421A1 (en) 2014-02-05
US20180291099A1 (en) 2018-10-11
ES2615387T3 (es) 2017-06-06
LT3173427T (lt) 2019-09-10
IL258914A (en) 2018-07-31
US20150209427A1 (en) 2015-07-30
HUE045943T2 (hu) 2020-02-28
ZA201307027B (en) 2016-08-31
US10597450B2 (en) 2020-03-24
US9828426B2 (en) 2017-11-28
CA2893376A1 (en) 2012-10-04
SMT201900505T1 (it) 2019-11-13
SI3173427T1 (sl) 2019-08-30
WO2012129668A1 (en) 2012-10-04
AU2012234754A1 (en) 2013-10-10
US9393302B2 (en) 2016-07-19
US20210054067A1 (en) 2021-02-25
EA038979B1 (ru) 2021-11-17
AU2012234754B2 (en) 2016-09-29
HRP20191590T1 (hr) 2019-11-29
EP3511345A1 (en) 2019-07-17
JP2014515600A (ja) 2014-07-03
MX2013011354A (es) 2014-06-11
KR20190074325A (ko) 2019-06-27
KR20140033014A (ko) 2014-03-17
CN103492418A (zh) 2014-01-01
IL228434B (en) 2018-05-31
MX352373B (es) 2017-11-22
EP3173427B1 (en) 2019-06-19
CN106146664A (zh) 2016-11-23
CA2829105C (en) 2019-09-24
PL3173427T3 (pl) 2019-11-29
US8937163B2 (en) 2015-01-20
DK3173427T3 (da) 2019-08-05
JP2018075018A (ja) 2018-05-17
US20140140990A1 (en) 2014-05-22
EA201391423A1 (ru) 2014-06-30
BR112013025198A2 (pt) 2018-12-04
IL228434A0 (en) 2013-12-31
EP2691421A4 (en) 2014-11-05
RS59080B1 (sr) 2019-09-30
NZ615694A (en) 2015-01-30
CA2888908A1 (en) 2012-10-04
US20160304605A1 (en) 2016-10-20
KR101993259B1 (ko) 2019-06-27

Similar Documents

Publication Publication Date Title
JP6294221B2 (ja) 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント
CA2740900C (en) Antibodies that specifically block the biological activity of a tumor antigen
JP6392435B2 (ja) 乳癌を治療する方法
HK40011472A (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
HK1238268B (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
HK1238268A1 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
HK1193835A (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
HK1193835B (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
NZ615694B2 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170530

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171207

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20171214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180215

R150 Certificate of patent or registration of utility model

Ref document number: 6294221

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees